XML 42 R27.htm IDEA: XBRL DOCUMENT v3.20.4
Collaboration and License Agreements - Takeda Pharmaceuticals U.S.A., Inc - Additional Information (Detail)
$ in Thousands
3 Months Ended
Oct. 07, 2020
USD ($)
Obligation
Bundle
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Jan. 31, 2021
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Revenues   $ 21,303 $ 29,455  
Takeda License Agreement | License and Co-Funding Agreement        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Agreement date Oct. 07, 2020      
Ratio of Profit Sharing Structure for United States Commercialization 50/50 profit sharing      
Number of distinct bundle | Bundle 1      
Number of distinct performance obligations | Obligation 1      
Initial transaction price $ 300,000      
Revenues   8,200 $ 0  
Contract assets   $ 8,200    
Takeda License Agreement | License and Co-Funding Agreement | Subsequent Event        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Cash received as due under collaboration agreement       $ 300,000
Takeda License Agreement | Minimum | License and Co-Funding Agreement        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Percentage of eligible to receive tiered royalties on net sales 20.00%      
Takeda License Agreement | Maximum | License and Co-Funding Agreement        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Percentage of eligible to receive tiered royalties on net sales 25.00%      
Development regulatory and sales milestones payments $ 740,000